19.8% rise in short interest for Milestone Pharmaceuticals (MIST) in February, with institutional investors increasing stock holdings.
Milestone Pharmaceuticals (MIST) saw a 19.8% rise in short interest in February, reaching 451,300 shares. Its lead product candidate, etripamil, is in Phase III trials for paroxysmal supraventricular tachycardia and Phase II trials for atrial fibrillation and rapid ventricular rate. Institutional investors including BlackRock and JPMorgan Chase have increased their stock holdings. Analysts give a consensus rating of "Moderate Buy" and a target price of $11.20.
March 18, 2024
3 Articles